Harvard Apparatus Regenerative Technology Welcomes Mao Zhang to Its Board of Directors
Holliston, MA -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a leading clinical-stage biotechnology firm specializing in organ regeneration technology, has announced the appointment of Mao Zhang as an independent director on its Board of Directors. This strategic move is designed to strengthen the company's business innovation, strategy, and financial management.
Mao Zhang, the Founder and Chief Executive Officer of StellarS Capital, brings over 15 years of expertise in the financial sector, particularly in hedge funds and private equity. His career began in 2007 at Magnetar Capital, where he was responsible for their Asian operations. Mr. Zhang earned his Bachelor of Science degree from the University of Pennsylvania.
A Valuable Addition to the Board
“We are excited to welcome Mao Zhang to the Board of Harvard Apparatus Regenerative Technology,” said Jerry He, Chairman of the company. “Mao's deep business and investment knowledge will be instrumental in our mission to meet the needs of patients. His joining us comes at a time filled with significant growth opportunities for the company.”
In his comments, Mr. Zhang shared his enthusiasm for joining the Board, stating, “I am thrilled to be part of the Board of Directors for Harvard Apparatus Regenerative Technology during this pivotal phase of its clinical development. The company is making strides in innovative cell therapies that could truly transform the lives of patients through organ regeneration. I look forward to aligning my efforts with the financial and strategic goals of Harvard Apparatus Regenerative Technology.”
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, Inc. is at the cutting edge of regenerative medicine, focusing on treatments for gastrointestinal disorders and other organ dysfunctions caused by cancer, trauma, or congenital defects. The company has developed a groundbreaking cell-therapy platform that utilizes a patient’s own stem cells to regenerate and restore damaged organs. This revolutionary approach not only offers a potential next-generation solution for organ function restoration but also reduces the reliance on donor organs or permanent artificial implants, significantly improving patient outcomes.
In 2017, Harvard Apparatus Regenerative Technology reached a landmark achievement by performing the world’s first successful esophagus regeneration in a patient with esophageal cancer. This groundbreaking surgery was conducted by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic, with the results published in the Journal of Thoracic Oncology Clinical and Research Reports.
Significant Achievements and Market Position
The company currently holds 15 U.S. patents, along with various patents granted in major international markets such as China, Japan, and Europe. Furthermore, Harvard Apparatus Regenerative Technology has received two orphan-drug designations in the United States, which can provide up to seven years of market exclusivity following FDA approval, as well as an orphan drug designation from the European Medicines Agency, granting ten years of market exclusivity in Europe after approval.
Contact for Investor Relations
For additional inquiries, Joseph Damasio, Chief Financial Officer, is available at 774-233-7330 or via email at jdamasio@hregen.com.
Frequently Asked Questions
What is the role of Mao Zhang in Harvard Apparatus Regenerative Technology?
Mao Zhang has been appointed as an independent director on the Board of Directors, with a focus on enhancing business innovation, strategic direction, and financial oversight.
What technology does Harvard Apparatus Regenerative Technology develop?
The company specializes in regenerative medicine treatments aimed at gastrointestinal disorders and other organ dysfunctions, primarily utilizing stem cells derived from patients.
What notable achievement does Harvard Apparatus Regenerative Technology have?
In 2017, the company successfully performed the first esophagus regeneration surgery, representing a significant breakthrough in organ regeneration technology.
How many patents does Harvard Apparatus Regenerative Technology hold?
Harvard Apparatus Regenerative Technology holds 15 issued patents in the United States and several issued patents in international markets.
What is the significance of orphan-drug designations for the company?
Orphan-drug designations provide market exclusivity, which can greatly enhance the company’s competitive position and financial prospects following regulatory approvals.
